(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) fell by a staggering 32.53% in 21 sessions from €0.21 to €0.14 at 19:09 EST on Wednesday, after two successive sessions in a row of gains. BEL 20 is sliding 0.52% to €3,666.07, after two successive sessions in a row of gains.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Volume
Today’s last reported volume for BIOSENIC is 90719 which is 92.34% below its average volume of 304183.
More news about BIOSENIC (BIOS.BR).
